Related references
Note: Only part of the references are listed.Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study
Carle Paul et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
Keith W. Pratz et al.
BLOOD (2010)
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
Michael Crump et al.
LEUKEMIA & LYMPHOMA (2010)
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor
Frank Breitenbuecher et al.
BLOOD (2009)
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Sabine Kayser et al.
BLOOD (2009)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Frank Breitenbuecher et al.
BLOOD (2009)
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin
Marcus M. Schittenhelm et al.
CELL CYCLE (2009)
Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor
Qi Chao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
Ketan S. Gajiwala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
Srdan Verstovsek et al.
CLINICAL CANCER RESEARCH (2008)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Carol Beadling et al.
CLINICAL CANCER RESEARCH (2008)
Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia
Victor Zota et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin
Salim Corbacioglu et al.
BLOOD (2006)
FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248)
M. M. Schittenhelm et al.
LEUKEMIA (2006)
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders:: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
Andres C. Garcia-Montero et al.
BLOOD (2006)
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor
Sebastian Bauer et al.
CANCER RESEARCH (2006)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21):: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT Isoforms associated with human malignancies
MM Schittenhelm et al.
CANCER RESEARCH (2006)
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
J Gotlib et al.
BLOOD (2005)
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
J Cools et al.
BLOOD (2004)
Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML
R Zheng et al.
LEUKEMIA RESEARCH (2004)
Biology of gastrointestinal stromal tumors
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
KWH Yee et al.
BLOOD (2004)
KIT mutations are common in testicular seminomas
K Kemmer et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia
S Ciolli et al.
LEUKEMIA & LYMPHOMA (2004)
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
W Fiedler et al.
BLOOD (2003)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
J Cools et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
FLT3 mutations in acute myeloid leukemia cell lines
H Quentmeier et al.
LEUKEMIA (2003)
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
A Pardanani et al.
BLOOD (2003)
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase
KWH Yee et al.
BLOOD (2002)
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
DA Tuveson et al.
ONCOGENE (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Share Paper
